Medidata Medidata

Small and Emerging Biopharma

Emerging Biopharma (EBP) drives the majority of trials and innovation in life sciences. However, median time for EBPs to launch new drugs is estimated to be 16.6 years, over 30% slower than other segments.²

EBPs are restricted by lean resources, limited access to sites and patients, lack of integrated systems, and risk of uncertain funding. A key success factor to address critical pain point is to assess the value and potential of clinical trial technologies.

How to control your data, simplify your trials, scale to your needs, maintain cost predictability, and accelerate your study success.

Medidata optimizes your patient enrollment, risk-proofs your data management, and gives you the agility to pivot your study while meeting regulatory and compliance requirements.


64% of FDA-approved drugs in 2018 originated from EBPs¹

73% of late-stage research are managed by EBPs¹

65% of all 2018 clinical trials were ran by EBPs, more than larger companies across all phases²


¹ Biotechs getting bigger in late-stage R&D, leaving Big Pharmas behind: report Fierce Biotech, April 2019

² IQVIA Institute, Emerging Biopharma’s Contribution to Innovation, June 2019


“The user interface is extremely intuitive to use, and the mobile app makes reviewing and approving SOPs while traveling so simple.”

Hayley Lewis
VP Regulatory & Compliance

Case Study

“Everything is there in one place. We can filter by site, we can filter by what’s been dispensed, and it’s really easy for us to track.”

Olivia Frank
Clinical Research Associate

Case Study

“Thanks to their robust data management platform, Medidata Rave has the capability to scale with us.”

John Lee
Chief Medical Officer

Case Study

“A lot of sites were happy to hear we were going over to Medidata.”

Patrick Zbyszewski
Director of Clinical Data Management

Case Study

Early phase studies

From challenges to successes

Clinical Trial Pain Points for Small & Mid Pharma

Control and Simplify Your Data Image

Control and Simplify Your Data

Unification across solutions simplifies the end-to-end management of your clinical trial. Gain control, visibility and continuity managing your data.

Avoid manual errors, repetitive data input while maintaining data integrity and meeting regulatory and compliance requirements.

Together, we will eliminate the need for multiple vendors and systems, through a truly unified platform, enabling you to manage your study and control your data better.

Scale as You Need Image

Scale as You Need

From local to global. From pre-study to later phases. From single to multi-study.

Gain the agility to scale, adapt and integrate as your trial evolves, as you need it, when you need it.

Together, we size and design your early phase clinical trial solutions to flexibly grow as you do.

Accelerate Your Study at Lower TCO Image

Accelerate Your Study at Lower TCO

Get optimal predictability to manage your budget. Achieve faster implementation time and overall lower cost.

Attract the best sites already using the best technology.

No additional integration or reconciliation charges, no hidden fees for reporting and analysis. Gain control, transparency and higher ROI through your study.

Together, we ensure your budget and resources deliver more.

EBP Master Class

Webinar Series

Consultants talk to Emerging Biopharma and Medical Device sponsors, providing practical learnings to avoid study pitfalls.

Why Medidata for Emerging Biopharma

3,000+ Phase 1 Studies

2,600+ Single Site Studies

500,000+ Site Relationships

~100% Revenue Retention Rate

1,200+ Small and EBP Sponsors Globally

130+ CRO, Services, and Partner Relationships

Phase Bio

"Medidata Rave has the capability to scale with us. We can monitor multiple studies in parallel and potentially merge data sets as needed."

John Lee, MD, PhD
Chief Medical Officer, PhaseBio